Introduction
============

Breast cancer as a malignant neoplasm originated from the breast tissues, is still the most common cause of women death worldwide despite advances made in both diagnosis and treatment ([@B1]).

microRNAs (miRNAs) are single-stranded non- coding RNAs with small size that regulate some of biological processes such as cell proliferation, differentiation, migration and apoptosis. miRNAs play roles in post-transcriptional modification of mRNAs by binding to the 3'-untranslated regions (3'-UTRs) through complementary base pairing ([@B2]), resulting in cleavage/degradation of the mRNA and consequently, translational repression ([@B3]). miRNAs can function as either oncomiRs or tumor suppressors ([@B4]). Owing to their potential ability to regulate numerous protein- encoding genes, miRNAs are regarded as a promising new target in the development of clinical treatments ([@B5]). miRNAs were found to be over-expressed in various human diseases including cancers ([@B6]). *miR-22* regulates estrogen receptor alpha (ERα) target genes by direct binding to ERα 3'-UTR region ([@B7]) through both destabilizing mRNA and inhibiting translation ([@B8]). *miR-22* increases the radiosensitivity of breast cancer cells and inhibits tumorgenesis by targeting Sirt 1 (silent information regulator 1) ([@B9]). Moreover, miR-22 down-regulates the proto-oncogene ATP citrate lyase which inhibits the growth and metastasis of breast cancer cells ([@B10]).

*miR-515-5p* controls cancer cell migration through modulation of MARK4 (microtubule affinity- regulating kinase 4) 3'-UTR region ([@B11]). The *miR-124* expression is significantly suppressed in breast cancer cells ([@B12]). *miR-124-3p* appears to be a tumor suppressor in breast cancer cells and it acts via targeting CBL (Cbl proto-oncogene, E3 ubiquitin protein ligase) ([@B13]). However, the molecular pathways underlying *miR-124* modulatory actions in breast cancer cells are not fully understood. Cyclin-dependent kinase 4 (CDK4), a master regulator of the cell cycle belonging to the CDK family ([@B14]), is identified as a major oncogenic driver among the cell cycle components ([@B15]); also, CDK4 has been found in several tumor types including breast ([@B16]) and lung cancers ([@B17]). It was shown that CDK4 is a target of miR-124 ([@B12]).

Development of breast cancer is closely associated with estrogen levels in the body. UDPglucuronosyltransferase (UGT) is an important class of phase 2 drug metabolizing enzymes that plays a pivotal role in detoxification of steroid compounds. UGTs eliminate estrogen hormones and influence estrogen signaling pathway ([@B18]). UGT2B isoforms are involved in regulating cell proliferation in human cancer cells. The UGT2B4, 2B7 and 2B15 isoforms are also involved in the glucuronidation of biologically active lipids ([@B19]). *miR-382-5p* regulates UGT2B15 and UGT2B17 isoforms ([@B20]). The Ras GTPase superfamily member RERG (Ras-related and estrogen- related growth inhibitor) reduces breast cancer cells proliferation and tumor formation. RERG was shown to play a regulatory role in the Ras/ERK pathway. *miR-382-5p* directly represses RERG; therefore, *miR-382- 5p* promotes viability, survival, migration and invasion of breast cancer cells ([@B21]).

The aryl hydrocarbon receptor (AhR) belongs to the family of basic helix-loop-helix nuclear transcription factors ([@B22]). The AhR downstream targets, cytochrome P450 (CYP1) isoforms, play bifunctional roles in detoxification or bioactivation of carcinogens, xenobiotics, and physiological compounds such as benzo(a)pyrene and estradiol ([@B23]). At the cellular level, AhR has functional interactions with signaling pathways governing cell proliferation and cell cycle, cell morphology, cell adhesion and cell migration ([@B24]). 6-formylindolo\[3,2-b\]carbazole (FICZ), a derivative of tryptophan (Trp) amino acid, is an ideal substrate for CYP1A1, 1A2, and 1B1 ([@B25]). FICZ also binds the AhR with the highest affinity known to date and thus, it reveals the characteristics of an endogenous signaling molecule ([@B26]-[@B28]). FICZ stimulates AhR-mediated activation of drug metabolizing enzymes such as CYP1A1 that end up its activity by generating a negative feedback control of its action ([@B22], [@B25], [@B27]-[@B29]).

This study was designed to reveal effects of FICZ, as an endogenous AhR ligand, on the expression levels of *miR22, miR-515-5p, miR-124-3p* and *miR-382-5p*in MCF-7 breast cancer cell line.

Materials and Methods
=====================

Chemicals
---------

6-formylindolo\[3,2-b\]carbazole (FICZ) was purchased from Syntastic AB, Sweden. 1-methyl-N\[ 2-methyl-4-\[2-(2-methylphenyl)diazenyl\] phenyl\]1H- pyrazole-5-carboxamide (CH223191) and 17ß-Estradiol (E2), dimethyl sulfoxide (DMSO) were bought from Sigma-Aldrich, Germany. All cell culture reagents and media were purchased from Invitrogen.

Cell culture and chemical treatments
------------------------------------

In this experimental study, MCF-7 cells were maintained in 10% fetal bovine serum (FBS)supplemented Dulbecco's modified Eagle's medium (DMEM) containing 100 µg/mL streptomycin, and 100 IU/mL penicillin under an atmosphere containing 5% CO~2~ at 37°C. Cells were treated with desired concentrations of chemicals, after replacing the growth medium with fresh medium without FBS. The final concentration of DMSO was 0.1% (v/v).

Small interfering RNA treatments
--------------------------------

SiRNA against ERα (Santa Cruz Biotechnology, CA, USA) was used for the targeted knockdown of ERα protein expression. Non-targeting scrambled siRNA (Santa Cruz Biotechnology, USA) was used as a control. MCF-7 cells were seeded in 6-well plates and grown in an antibiotic-free medium containing 5% FBS. At 50-60% confluence, the cells were transfected with 100 nM ERα siRNA or scrambled siRNA using lipofectamine 2000 (Invitrogen, USA) in 1 ml of transfection medium (Santa Cruz Biotechnology, USA). After 5 hours, the medium was replaced with fresh medium and 3 hours later, the cells were treated with DMSO, FICZ (1 nM), E2 (10 nM), and CH223191 (10 nM) for 18 hours.

RNA extraction and cDNA synthesis of miRNAs
-------------------------------------------

The TRizol reagent (Invitrogen, Carlsbad, CA, USA) was used for isolation of total RNA according to the manufacturer's instructions; then, total RNAwas reversely transcribed into cDNA by using the RT microRNA Kit (EXIQON, Denmark). The ERα mRNA in the cells was quantified by using the following primers:

F: 5´-GTTCTTAGTGGCACATCTTCTG-3´

R: 5´-GAATCCTCACGCTTAGTAACATAG-3´.

Real-time reverse transcription polymerase chain reaction (RT-PCR) amplification consisted of 40 cycles (95°C for 5 seconds, 63°C for 20 seconds, and 72°C for 30 seconds) after an initial denaturation done at 95°C for 5 minutes in an ABI StepOne™ real-time quantitative PCR system. The fold change of the miRNA expression was calculated by using the 2^-ΔΔCt^ method after normalization against the 5S rRNA (used as internal control) expression.

Statistical analysis
--------------------

Statistical significance was determined by one-way ANOVAand Tukey test. The results are expressed as means ± SD for at least three separate (replicate) experiments for each treatment group in the *in vitro* studies. P\<0.05 were considered statistically significant.

Results
=======

Effect of ERα on the expression of *miR-22, mir-515-5p, miR-124-3p* and *miR-382-5p*, in MCF-7 cells
----------------------------------------------------------------------------------------------------

In this study, MCF-7 cells were treated with E2 (10 nM) and our results revealed that *miR-22, miR-515-5p,* and *miR-124-3p* expressions were significantly increased and miR-382-5p were decreased. The expression of *miR-22, miR-515-5p,* and *miR-124-3p* were respectively 8, 2.46, and 2.29 times higher in the ERα-silenced cells than scrambled ones ([Fig .1](#F1){ref-type="fig"}).

![Expressions of *miR-22, miR-515-5p,* and *miR-124-3p* were inversely correlated with ERα in MCF-7. The cells were treated with E2 (10 nM) and the levels of *miR-22, miR-515-5p, miR-124-3p* and *miR-382-5P* were measured using real-time RT-PCR. Values are expressed as means ± SE. Asterisks denote significant differences (\*\*\*; P\<0.001) between control and other treated groups and significant differences (+++; P\<0.001) between cells treated with siRNA and those treated with scrambled siRNA. ERα; Estrogen receptor alpha and RT-PCR; Real-time reverse transcription polymerase chain reaction.](Cell-J-22-115-g01){#F1}

Effect of AhR on the expression of *miR-22, mir-515-5p, miR-124-3p* and *miR-382-5p,* in MCF-7 cells
----------------------------------------------------------------------------------------------------

MCF-7 cells were treated with an AhR agonist, FICZ (1 nM) or an AhR antagonist, CH223191 (10 nM) either alone or in combinations, our data showed that the *miR-22, miR515-5p,* and *miR-124-3p* expression levels were significantly increased by FICZ and CH223191 treatments. The expression of *miR-22, miR515-5p,* and *miR-124-3p* in FICZ, CH223191 and FICZ+CH223191 treated groups were respectively 12.55, 7.94, 7.46; 4.75, 2.21, 3.7 and 8.69, 2.29, 5.27 times higher than the control group (Figes[.2](#F2){ref-type="fig"}[](#F3){ref-type="fig"}-[4](#F4){ref-type="fig"}). *miR-382-5p* expression levels significantly decreased in cells treated with FICZ+ CH223191 ([Fig .5](#F5){ref-type="fig"}).

![Expression of *miR-22* was AhR-dependent in MCF-7. The quantitative RT-PCR analysis showed that the expression level of *miR-22* was much higher in the cells treated with FICZ in comparison to control. Values are expressed as mean ± SE. Asterisks denote significant differences (\*\*\*; P\<0.001) between control and other treated groups and significant differences (++; P\<0.001) between cells treated with FICZ and the cells treated with FICZ+ CH223191. AhR; Aryl hydrocarbon receptor, RT-PCR; Real-time reverse transcription polymerase chain reaction, and FICZ; 6-formylindolo\[3,2-b\]carbazole.](Cell-J-22-115-g02){#F2}

![Expression of *miR-515-5p* was AhR-dependent in MCF-7. The quantitative RT-PCR analysis showed that the expression levels of *miR-515- 5p* were much higher in the cells treated with FICZ in comparison to control. Values are expressed as mean ± SE. Asterisks denote significant differences(\*\*; P\<0.01 and \*\*\*; P\<0.001) between control and other treated groupsand significant differences (+; P\<0.05) between cells treated with FICZ andthe cells treated with FICZ+ CH223191. AhR; Aryl hydrocarbon receptor, RT- PCR; Real-time reverse transcription polymerase chain reaction, and FICZ; 6-formylindolo\[3,2-b\]carbazole.](Cell-J-22-115-g03){#F3}

![Expression of *miR-124-3p* was AhR-dependent in MCF-7. The quantitative RT-PCR analysis showed that the expression levels of *miR- 124-3p*were much higher in the cells treated with FICZ in comparison to control. Values are expressed as mean ± SE. Asterisks denote significant differences (\*; P\<0.05 and \*\*\*; P\<0.001) between control and other treated groups. AhR; Aryl hydrocarbon receptor, RT-PCR; Real-time reverse transcription polymerase chain reaction, and FICZ; 6-formylindolo\[3,2-b\] carbazole.](Cell-J-22-115-g04){#F4}

![Expression of miR-382-5p was AhR-dependent in MCF-7. The quantitative RT-PCR analysis showed that the expression levels of miR- 382-5p were much lower in the cells treated with FICZ+CH223191 in comparison to control.. Values are expressed as mean ± SE. Asterisks denote significant differences (\*\*; P\<0.01) between control and other treated groups. AhR; Aryl hydrocarbon receptor, RT-PCR; Real-time reverse transcription polymerase chain reaction, and FICZ; 6-formylindolo\[3,2-b\] carbazole.](Cell-J-22-115-g05){#F5}

Discussion
==========

miRNAs are stable biomarkers as they have high stability in extreme conditions such as low pH and high temperatures ([@B30]) and are used as prognostic and therapeutic tools for breast cancer ([@B31]).

In ERα silencing cells, we observed significantly increased expression levels of *miR-22, miR-515-5p,* and *miR-124-3p*. Furthermore, FICZ treatments led to over- expression of *miR-22, miR-515-5p,* and *miR-124-3p*.

*miR-22* regulates ERα target genes by direct binding to the ERα 3'-UTR region ([@B7]) through both destabilizing and inhibiting translation of mRNA ([@B8]). *miR-22* represses CD147 expression by directly targeting the *CD147* 3'UTR site. miR-22 also indirectly participates in the CD147 modulation by down-regulating Sp1. Indeed, *CD147*is overexpressed in breast cancer tissues, and its high expression is correlated with tumor invasion and metastasis ([@B32]). The transcription factors Sp1 could bind to the *CD147* promoter and enhance its expression as well. In addition, low miR22 levels are significantly associated with poor differentiation of breast cancer cells. Furthermore, *SIRT1* (Sirtuin1) expression levels are significantly up-regulated in breast cancer tissues. Since *miR22* has suppressive effects on breast cancer cells via targeting *SIRT1*, miR22/SIRT1 axis may be used as a novel and potential therapeutic target for breast cancer treatment ([@B33]).

Sphingo kinase-1 (SK1) mediates cell proliferation in cancer cells. *miR-515-5p* targets SK1 and inhibits breast cancer cells growth. Previous studies reported that SK1 mediates estrogen-dependent tumorigenesis in MCF-7 cells and estradiol down-regulates *miR-515-5p* expression but increases SK1 activity ([@B34]). *miR-124* targets Slug (SNAI2, transcriptional repressor of E-cadherin) and regulates epithelial-mesenchymal transition and metastasis of breast cancer cells ([@B35]). miR-124 also suppresses breast cancer cells growth and motility by targeting CD151 ([@B36]). Moreover, *miR-124-3p* inhibits tumor metastasis by inhibiting *PDCD6* expression. In this regard, miR-124-3p/PDCD6 signaling axis may be a potential target for treatment of patients with advanced breast cancer.

Our results showed that ERα silencing significantly led to *miR-382-5p* down-regulation. *miR-382-5p* targets UDP-glucuronosyl transferases (UGTs) ([@B20]) which are involved in the detoxification of estrogen derivatives ([@B18]). Thus, *miR-382-5p* down-regulation may enhance estrogen detoxification. One of the new findings of the present study was that ERα silencing or FICZ treatment led to up- regulation of *miR-22, miR-515-5p,* and *miR-124-3p*. ERα suppresses Drosha (one of the main processing enzymes in miRNA biogenesis) activity in MCF-7 cells ([@B37]). Therefore, we suggest that silencing ERα may enhance tumor suppressor miRNAs such as *miR-22, miR-515-5p* and *miR-124-3p*.

A number of studies reported that AhR-ARNT complex may reduce ERα-mediated transactivation ([@B38]) either directly by binding the inhibitory site of XRE (iXRE) or by employing shared coactivators ([@B39]).

Some reports also indicated that ERα can be activated by AhR agonists, but not by AhR antagonists ([@B40]). However, AhR antagonists may exhibit a partial effect.

Conclusion
==========

Our data demonstrated that the overexpression of tumor suppressor miRNAs including *miR-22, miR-515-5p,* and *miR-124-3p* by FICZ, as an AhR agonist, might be considered a potential therapeutic approach against breast cancer.
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